SCHOTT PHAR.AG ADR

Supplier SCHOTT Pharma increased group sales in the first half to the end of March by around 1% to €488.1 million. EBITDA remained almost at last year’s level at €129.8 million, despite a one-off impairment on customer-specific glass syringes. The result was driven by continued strong demand for sterile vials and carpules; CEO Christian Mias described the outcome as on plan. CFO Reinhard Mayer highlighted lower receivables and a markedly higher free cash flow; the annual targets were confirmed. » Más en finanzen.net

SCHOTT Pharma reported a surprisingly strong, profitable first quarter thanks to rising demand for high-margin, high-value solutions such as ready-to-use cartridges and specialty vials. Currency-adjusted revenue rose by about 5% to €240.2 million, EBITDA grew by over 11% to €65.2 million, and the EBITDA margin was 27.1%. Management confirms the revenue and earnings guidance for 2026 and expects currency-adjusted full-year revenue growth of 2–5% and an operating margin of around 27%. Group CEO Andreas Reisse will hand over leadership in May to Christian Mias. » Más en finanzen.net

BaFin reported an insider trade on 18 December 2025: board member Mayer, Reinhard, acquired 2,999 SCHOTT Pharma shares at €14.93 each. In the FSE session the price subsequently fell to €14.70. SCHOTT Pharma has a market capitalization of around €2.21 billion and 150,614,608 tradable shares. » Más en finanzen.net